History

Orforglipron was discovered by Chugai Pharmaceutical (originally coded OWL-833) and licensed to Eli Lilly in 2018, which advanced it as LY3502970. It was designed as a synthetic small molecule to overcome the poor oral bioavailability that forces peptide GLP-1 drugs to be injected. After Phase 1 studies in 2023, a Phase 2 obesity trial (NEJM, 2023) and the Phase 3 ATTAIN and ACHIEVE programs, the FDA approved it on April 1, 2026 as Foundayo for chronic weight management — the first oral small-molecule GLP-1 receptor agonist approved, and the first GLP-1 pill with no food, water, or time-of-day restrictions.

Orforglipron (brand name Foundayo) is a GLP-1 receptor agonist — the same drug class as semaglutide and tirzepatide — but with one defining difference: it is a small molecule, not a peptide, and it is taken as a once-daily pill rather than an injection. In April 2026 the FDA approved it for chronic weight management, making it the first oral small-molecule GLP-1 drug on the market. Because the existing GLP-1 drugs are peptides that the gut breaks down, getting this mechanism into a convenient daily pill has been a long-standing goal, and orforglipron is the first to clear that bar with a clean regulatory approval and a substantial Phase 3 dataset behind it.

What it is

Orforglipron is an oral, non-peptide GLP-1 receptor agonist. That phrasing matters: it is a synthetic small molecule, not a peptide. Peptide GLP-1 drugs (semaglutide, liraglutide, tirzepatide) are degraded by enzymes in the gut, which is why they are injected — and why even oral semaglutide must be taken under strict fasting and water conditions. Orforglipron was engineered as a small molecule specifically to sidestep that problem.

Mechanistically, it is described as an allosteric, G-protein–biased partial agonist of the GLP-1 receptor: it binds a transmembrane site and is biased toward Gs/cAMP signaling over β-arrestin. The downstream effects are the standard GLP-1 axis — glucose-dependent insulin secretion, slowed gastric emptying, and central appetite suppression. Its pharmacokinetics support once-daily oral dosing with no food, water, or timing restrictions; the half-life is dose- and time-dependent, roughly 25–35 hours after a single dose and rising to roughly 48–68 hours at steady state.

It originated at Chugai Pharmaceutical (development code OWL-833) and was licensed to Eli Lilly in 2018, which carried it forward as LY3502970 and ultimately as Foundayo.

The claims

The compound is presented as an oral GLP-1 pill that delivers injection-class weight loss without an injection and without dietary restrictions. The specific things worth checking are: how much weight people actually lose, whether it works for type 2 diabetes, whether it is a peptide (it is not), whether it preserves muscle, and what its anti-doping status is. Some online claims also assert it has been moved to a banned status by anti-doping authorities — that claim is examined below and does not hold up.

What the evidence actually shows

The human evidence here is genuinely strong — multiple large Phase 3 trials published in major journals, plus an FDA approval.

Weight management (no diabetes) — ATTAIN-1. This Phase 3 trial (NCT05869903, NEJM 2025) ran 72 weeks in adults with obesity. At the highest dose, mean weight loss was up to roughly 12.4% on the efficacy estimand (about 11% on the treatment-regimen estimand), versus about 2.1% on placebo — with lower doses landing in between. A majority of participants on the higher doses achieved at least 10% weight loss. The trial enrolled roughly 3,000+ participants across multiple countries.

Weight plus type 2 diabetes — ATTAIN-2. This Phase 3 trial (NCT05872620, The Lancet, November 2025) studied adults with obesity and type 2 diabetes over 72 weeks. The highest dose produced up to roughly 10.5% weight loss with an A1C reduction of roughly 1.8%.

Phase 2 (obesity). The earlier NEJM 2023 trial showed up to roughly 14.7% mean weight reduction at 36 weeks, establishing the signal that the Phase 3 program confirmed.

Maintenance — ATTAIN-MAINTAIN. A Phase 3b trial (NCT06584916, Nature Medicine) tested orforglipron for maintaining weight loss after an injectable incretin and met its primary and key secondary endpoints.

Diabetes program — ACHIEVE. The ACHIEVE-3 head-to-head trial (The Lancet, February 2026) found the 36 mg dose superior to oral semaglutide on A1C (−2.2% vs −1.4%) and on weight. Other ACHIEVE trials met endpoints per Lilly topline readouts.

Muscle. There is no credible orforglipron-specific data showing muscle or lean-mass preservation. It is a metabolic and weight-loss agent, not a muscle agent — any “muscle” claim is unsupported.

Preclinical. The receptor structural and biased-signaling characterization is preclinical pharmacology. Notably, orforglipron was not pharmacologically active in the rodent species tested and did not produce rodent tumors, which is relevant to the precautionary thyroid warning discussed below.

Legal and regulatory status

Orforglipron is FDA-approved (April 1, 2026) as Foundayo for chronic weight management — for adults with obesity, or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity. It is the first oral small-molecule GLP-1 receptor agonist approved, and the first GLP-1 pill with no food, water, or time-of-day restrictions. The approval came through the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot, on a notably fast timeline (it was the first new molecular entity approved under that program).

Type 2 diabetes is not yet approved as of June 2026. The Phase 3 ACHIEVE program supports a diabetes indication and a regulatory filing was expected in 2026, but approval has not occurred. It should not be described as approved for diabetes.

Anti-doping. Orforglipron is a GLP-1 receptor agonist, and that class is not on the WADA 2026 Prohibited List — it is not prohibited in or out of competition. GLP-1 receptor agonists are on WADA’s 2026 Monitoring Program, meaning they are under surveillance only, with no sanctions; monitoring data may inform future decisions. A claim circulating online that WADA “moved GLP-1 drugs to full S4 prohibition in January 2026” appears to be false — it traces to a non-authoritative vendor blog and is contradicted by WADA’s own Monitoring Program document and by medical and sports-law sources. The status is monitored, not prohibited. (For contrast, growth-factor agents like MGF and IGF-1 variants are prohibited under WADA Category S2; orforglipron is a small-molecule incretin-pathway drug, not a growth factor, and is not in S2.)

Safety

Orforglipron carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN-2. This warning is precautionary and class-based: orforglipron was not pharmacologically active in the rodent species tested and did not produce rodent tumors.

The most common adverse effects are gastrointestinal and class-typical: nausea, vomiting, diarrhea, constipation, and belching — mostly mild to moderate, dose-related, and front-loaded during dose titration. In ATTAIN-1, nausea was roughly one-third of participants at higher doses, and adverse-event-related discontinuations rose with dose to around 10% versus roughly 3% on placebo (precise per-dose figures should be read from the NEJM paper itself).

Notably, ATTAIN-1 showed no hepatic safety signal — relevant because liver-enzyme elevations derailed some other oral small-molecule GLP-1 candidates (including a discontinued Pfizer program). Standard GLP-1 cautions otherwise apply: pancreatitis, gallbladder events, diabetic retinopathy in diabetes, and hypoglycemia when combined with insulin or sulfonylureas. Long-term cardiovascular-outcome and durability data are still maturing.

Bottom line

Orforglipron is one of the better-evidenced compounds in this space: a non-peptide, oral, once-daily GLP-1 receptor agonist with several large published Phase 3 trials and a clean FDA approval (Foundayo, April 2026) for chronic weight management. Top-dose weight loss runs to roughly 12.4% in obesity without diabetes and roughly 10.5% with diabetes. It is not yet approved for type 2 diabetes. It is a small molecule, not a peptide. There is no evidence it preserves or builds muscle. Its drug class is monitored — not banned — by WADA, and the “now prohibited” rumor is unsupported. The main open questions are long-term cardiovascular outcomes and durability, plus the standard GLP-1 cautions and a precautionary thyroid boxed warning.

Evidence grade: Strong human.